Simpson Emmanuel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India Business News: Despite a tendency of lower exposure and slow performance among most pharmaceutical MNCs in India, Swiss biotech behemoth Roche is defying the trend.

India's pharma sector on Wednesday said the Goods and Services Tax (GST) Council's decision to exempt tax on rare diseases drugs is unlikely to benefit the population unless the waiver is extended to drugs that are made commercially available in the country. The GST Council on Tuesday (July 11) said the Integrated Goods and Services Tax (IGST) on medicines and Food for Special Medical Purposes (FSMP) used for treating rare diseases enlisted under the National Policy for Rare Diseases, 2021, will be exempt when imported for personal use subject to existing conditions. 'We support the government...

PINK Project initiative to help address gaps in breast cancer treatment launched in Punjab

Last Updated: All About Roche's COVID Antibody Cocktail That India Approved As Treatment For Mild Cases A Switzerland based drug maker, Roche has received approval from India's Central Drugs Standards Control Organisation (CDSCO) for COVID-19 emergency use . Image: PTI Widening the arsenal of drugs to combat COVID-19, a Switzerland-based drug maker, Roche has received approval from India's Central Drugs Standards Control Organisation (CDSCO) for use in emergency situations for treatment of COVID-19. The said experimental antibody cocktail was consumed by former US President Donald Trump...

Last Updated: India Approves Roche's Antibody Cocktail COVID Treatment For Mild Cases; Trump Had Taken The Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Roche for the antibody cocktail. Expanding its arsenal of drugs to battle the massive second wave of COVID-19, the Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Swiss pharma company Roche for the antibody cocktail 'Casirivimab and Imdevimab' in India. The decision was taken based on data filed with the ...